News Medical on MSN4h
Peyronie's disease management Current insights & Future directions
Peyronie's disease (PD) causes penile curvature. Its etiology is multifactorial, involving microtrauma and genetic factors.
Hosted on MSN18d
Endo, Inc. Shares Positive Data on XIAFLEX Treatment for Peyronie’s Disease
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the ...
Endo Launches Spatial Computing Simulator to Create a Fully Immersive Learning Environment for Hand Specialists
Endo, Inc. (OTCQX: NDOI) announced today the launch of a first-of-its-kind initiative for a pharmaceutical company: the ...
Morningstar1mon
Endo Launches "Steve's Journey," the First Branded Dupuytren's Contracture Commercial for XIAFLEX® (collagenase clostridium histolyticum)
The campaign, featuring a real Dupuytren's contracture patient, encourages patients to consult a hand specialist and ask about XIAFLEX® (collagenase clostridium histolyticum), the only FDA ...
Morningstar9d
Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
MALVERN, Pa., March 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment of ...
Longview News-Journal21d
Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the Southeastern Section of the American Urological Association
March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum, or CCH ...
Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or ...
Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the Southeastern Section of the American Urological Association
Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in patients with Peyronie's disease (PD) ...